# A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects

> **NCT07014488** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** HRS-5041 Tablets
- **DRUG:** Rifampicin Capsule

## Key facts

- **NCT ID:** NCT07014488
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-20
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014488, "A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07014488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*